Upregulation of DLC‑1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model

Chen,Bo; Xu,Mingzheng; Xu,Ming

doi:10.3892/ol.2019.10871

Upregulation of DLC‑1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model

Authors:
- Bo Chen
- Mingzheng Xu
- Ming Xu
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Shanghai East Hospital Affiliated to Tongji University, Shanghai 200120, P.R. China, Department of Emergency, Shanghai East Hospital Affiliated to Tongji University, Shanghai 200120, P.R. China, Department of Gastroenterology, Dongfang Hospital Affiliated to Tongji University, Shanghai 200120, P.R. China
Published online on: September 16, 2019 https://doi.org/10.3892/ol.2019.10871
Pages: 5600-5606

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deleted in liver cancer 1 (DLC‑1) serves a vital role in the progression of multiple cancers, including those of the pancreas. Numerous studies have aimed to reveal the anti‑cancer mechanisms of the DLC‑1 gene, though few have focused on its impact on the development of pancreatic cancer. Using clinical pancreatic cancer samples and pancreatic cancer cell lines, the present study aimed to reveal the role of DLC‑1 in this disease. The expression levels of DLC‑1 were determined in pancreatic cancer and adjacent normal tissues from patients with pancreatic cancer, indicating a decreased expression level of DLC‑1 in cancerous tissues. Using the pancreatic cancer cell line SW1990, the effect of DLC overexpression on cell proliferation, invasive capacity and the cell cycle and were assessed. Using a mouse tumor model, the tumor‑progression capacity of transfected and untransfected SW1990 cells was investigated, indicating that DLC‑1 transfection reduced the capacity for tumor progression. Thus, the present study indicated that the overexpression of DLC‑1 inhibited the proliferation and reduced the invasive capacity of SW1990 cells both in vitro and in vivo, and that it may have significant inhibitory effects on the development of pancreatic cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, et al: The genomic landscape of pancreatic and periampullary adenocarcinoma. Cancer Res. 76:5092–5102. 2016. View Article : Google Scholar : PubMed/NCBI
3	Kang MJ, Jang JY, Kwon W and Kim SW: Clinical significance of defining borderline resectable pancreatic cancer. Pancreatology. 18:139–145. 2018. View Article : Google Scholar : PubMed/NCBI
4	Bhosale P, Cox V, Faria S, Javadi S, Viswanathan C, Koay E and Tamm E: Genetics of pancreatic cancer and implications for therapy. Abdom Radiol (NY). 43:404–414. 2018. View Article : Google Scholar : PubMed/NCBI
5	Treves S, Feriotto G, Moccagatta L, Gambari R and Zorzato F: Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco(endo)plasmic reticulum membrane. J Biol Chem. 275:39555–39568. 2000. View Article : Google Scholar : PubMed/NCBI
6	Zhou XL, Thorgeirsson SS and Popescu NC: Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene. 23:1308–1313. 2004. View Article : Google Scholar : PubMed/NCBI
7	Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC and Reynolds SH: DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene. 23:1405–1411. 2004. View Article : Google Scholar : PubMed/NCBI
8	Ng IO, Liang ZD, Cao L and Lee TK: DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res. 60:6581–6584. 2000.PubMed/NCBI
9	Basak P, Dillon R, Leslie H, Raouf A and Mowat MR: The deleted in liver cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity. BMC Cancer. 15:6302015. View Article : Google Scholar : PubMed/NCBI
10	Ullmannova-Benson V, Guan M, Zhou X, Tripathi V, Yang XY, Zimonjic DB and Popescu NC: DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia. 23:383–390. 2009. View Article : Google Scholar : PubMed/NCBI
11	Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, et al: DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Gene Dev. 22:1439–1444. 2008. View Article : Google Scholar : PubMed/NCBI
12	Lahoz A and Hall A: DLC1: A significant GAP in the cancer genome. Gene Dev. 22:1724–1730. 2008. View Article : Google Scholar : PubMed/NCBI
13	Wuestefeld T and Zender L: DLC1 and liver cancer: The Akt connection. Gastroenterology. 139:1093–1096. 2010. View Article : Google Scholar : PubMed/NCBI
14	Song LJ, Liu Q, Meng XR, Li ShL, Wang LX, Fan QX and Xuan XY: DLC-1 is an independent prognostic marker and potential therapeutic target in hepatocellular cancer. Diagn Pathol. 11:192016. View Article : Google Scholar : PubMed/NCBI
15	Shih YP, Takada Y and Lo SH: Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells. Mol Cancer Res. 10:34–39. 2012. View Article : Google Scholar : PubMed/NCBI
16	Xue YZ, Wu TL, Wu YM, Sheng YY, Wei ZQ, Lu YF, Yu LH, Li JP and Li ZS: DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. Tumor Biol. 34:2857–2861. 2013. View Article : Google Scholar
17	Popescu NC and Goodison S: Deleted in liver cancer-1 (DLC1): An emerging metastasis suppressor gene. Mol Diagn Ther. 18:293–302. 2014. View Article : Google Scholar : PubMed/NCBI
18	Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG and Lowy DR: Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA. 104:9012–9017. 2007. View Article : Google Scholar : PubMed/NCBI
19	Qian X, Durkin ME, Wang D, Tripathi BK, Olson L, Yang XY, Vass WC, Popescu NC and Lowy DR: Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer. Cancer Res. 72:5900–5911. 2012. View Article : Google Scholar : PubMed/NCBI
20	Ko FC and Ping Yam JW: Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation. Int J Cancer. 135:264–269. 2014. View Article : Google Scholar : PubMed/NCBI
21	Ullmannova V and Popescu NC: Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol. 29:1127–1132. 2006.PubMed/NCBI
22	Dai ZS and Jin YL: Promoter methylation of the DLC-1 gene and its inhibitory effect on human colon cancer. Oncol Rep. 30:1511–1517. 2013. View Article : Google Scholar : PubMed/NCBI
23	Li GR, Du XL, Vass WC, Papageorge AG, Lowy DR and Qian XL: Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci USA. 108:17129–17134. 2011. View Article : Google Scholar : PubMed/NCBI
24	Palombella S, Pirrone C, Cherubino M, Valdatta L, Bernardini G and Gornati R: Identification of reference genes for qPCR analysis during hASC long culture maintenance. PLoS One. 12:e01709182017. View Article : Google Scholar : PubMed/NCBI
25	Wang C, Wang J, Liu H and Fu Z: Tumor suppressor DLC-1 induces apoptosis and inhibits the growth and invasion of colon cancer cells through the wnt/beta-catenin signaling pathway. Oncol Rep. 31:2270–2278. 2014. View Article : Google Scholar : PubMed/NCBI
26	Boulter N, Suarez FG, Schibeci S, Sunderland T, Tolhurst O, Hunter T, Hodge G, Handelsman D, Simanainen U, Hendriks E and Duggan K: A simple, accurate and universal method for quantification of PCR. BMC Biotechnol. 16:272016. View Article : Google Scholar : PubMed/NCBI
27	Larionov A, Krause A and Miller W: A standard curve based method for relative real time PCR data processing. Bmc Bioinformatics. 21:622005. View Article : Google Scholar
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 98:5116–5121. 2001. View Article : Google Scholar : PubMed/NCBI
30	Diboun I, Wernisch L, Orengo CA and Koltzenburg M: Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
31	Zhou X, Xu X, Wang J, Lin J and Chen W: Identifying miRNA/mRNA negative regulation pairs in colorectal cancer. Sci Rep. 5:129952015. View Article : Google Scholar : PubMed/NCBI
32	Zhang P, Qiao Y, Wang C, Ma L and Su M: Enhanced radiation therapy with internalized polyelectrolyte modified nanoparticles. Nanoscale. 6:10095–10099. 2014. View Article : Google Scholar : PubMed/NCBI
33	Nakano T, Kanai Y, Amano Y, Yoshimoto T, Matsubara D, Shibano T, Tamura T, Oguni S, Katashiba S, Ito T, et al: Establishment of highly metastatic KRAS mutant lung cancer cell sublines in long-term three-dimensional low attachment cultures. PLoS One. 12:e01813422017. View Article : Google Scholar : PubMed/NCBI
34	Neuhoff V, Stamm R, Pardowitz I, Arold N, Ehrhardt W and Taube D: Essential problems in quantification of proteins following colloidal staining with coomassie brilliant blue dyes in polyacrylamide gels, and their solution. Electrophoresis. 11:101–117. 1990. View Article : Google Scholar : PubMed/NCBI
35	Esmaeelian B, Benkendorff K, Johnston MR and Abbott CA: Purified brominated indole derivatives from dicathais orbita induce apoptosis and cell cycle arrest in colorectal cancer cell lines. Mar Drugs. 11:3802–3822. 2013. View Article : Google Scholar : PubMed/NCBI
36	Braun AC and Olayioye MA: Rho regulation: DLC proteins in space and time. Cell Signal. 27:1643–1651. 2015. View Article : Google Scholar : PubMed/NCBI
37	Yam JW, Ko FC, Chan CY, Jin DY and Ng IO: Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 66:8367–8372. 2006. View Article : Google Scholar : PubMed/NCBI
38	Kim TY, Jackson S, Xiong Y, Whitsett TG, Lobello JR, Weiss GJ, Tran NL, Bang YJ and Der CJ: CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proc Natl Acad Sci USA. 110:16868–16873. 2013. View Article : Google Scholar : PubMed/NCBI
39	Wong CC, Wong CM, Ko FC, Chan LK, Ching YP, Yam JW and Ng IO: Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One. 23:e27792008. View Article : Google Scholar
40	Cao X, Kaneko T, Li JS, Liu AD, Voss C and Li SS: A phosphorylation switch controls the spatiotemporal activation of rho GTPases in directional cell migration. Nat Commun. 6:77212015. View Article : Google Scholar : PubMed/NCBI
41	Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI and Lowy DR: Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Cancer Res. 72:4405–4416. 2012. View Article : Google Scholar : PubMed/NCBI